Individual differences in response to antidepressants: a meta-analysis of placebo-controlled randomized clinical trials

Individual differences in response to antidepressants: a meta-analysis of placebo-controlled randomized clinical trials

<p><strong>Importance</strong> Antidepressants are commonly used to treat major depressive disorder (MDD). Antidepressant outcomes can vary based on individual differences; however, it is unclear whether specific factors determine this variability or whether it is at random.</p&...

Descrizione completa

Dettagli Bibliografici
Autori principali:	Maslej, MM, Furukawa, TA, Cipriani, A, Tomlinson, A, Et al.
Natura:	Journal article
Lingua:	English
Pubblicazione:	American Medical Association 2021

Documenti analoghi

HOW IMPORTANT IS PLACEBO IN ANTIDEPRESSANT TRIALS?
di: Cipriani, A
Pubblicazione: (2010)

Impact of placebo arms on outcomes in antidepressant trials: systematic review and meta-regression analysis
di: Salanti, G, et al.
Pubblicazione: (2018)

Exploratory analyses of effect modifiers in the antidepressant treatment of major depression: Individual-participant data meta-analysis of 2803 participants in seven placebo-controlled randomized trials
di: Noma, H, et al.
Pubblicazione: (2019)

Efficacy of antidepressants over placebo is similar in two-armed versus three-armed or more-armed randomized placebo-controlled trials.
di: Ogawa, Y, et al.
Pubblicazione: (2017)

Antidepressants versus placebo for panic disorder in adults
di: Bighelli, I, et al.
Pubblicazione: (2018)

Assessment of blinding in randomized controlled trials of antidepressants for depressive disorders 2000–2020: a systematic review and meta-analysis
di: Lin, Y-H, et al.
Pubblicazione: (2022)

Development and validation of a prediction model for the probability of responding to placebo in antidepressant trials: a pooled analysis of individual patient data
di: Shinohara, K, et al.
Pubblicazione: (2019)

Relationship between quality of reports of antidepressant randomized controlled trials and treatment estimates: systematic review, meta-analysis, and meta-regression analysis.
di: Cipriani, A, et al.
Pubblicazione: (2007)

Is placebo response in antidepressant trials rising or not? A reanalysis of datasets to conclude this long-lasting controversy.
di: Furukawa, T, et al.
Pubblicazione: (2018)

Possibly no baseline severity effect for antidepressants versus placebo but for antipsychotics. Why?
di: Leucht, S, et al.
Pubblicazione: (2018)

Assessment of blinding in randomized controlled trials of antidepressants for depressive disorders 2000–2020: A systematic review and meta-analysis
di: Yi-Hsuan Lin, et al.
Pubblicazione: (2022-08-01)

DSM-III-R change in definition might have affected placebo response to antidepressants - Authors' reply
di: Cipriani, A, et al.
Pubblicazione: (2017)

Placebo response rates in antidepressant trials: a systematic review of published and unpublished double-blind randomised controlled studies
di: Furukawa, T, et al.
Pubblicazione: (2016)

Network meta-analysis of antidepressants - Authors' reply
di: Cipriani, A, et al.
Pubblicazione: (2018)

Interindividual differences in anhedonia moderate antidepressant placebo responses on heart rate in healthy individuals
di: Li-Ching Chuang, et al.
Pubblicazione: (2024-01-01)

Personalise antidepressant treatment for unipolar depression combining individual choices, risks and big data (PETRUSHKA): rationale and protocol
di: Tomlinson, A, et al.
Pubblicazione: (2019)

Antidepressants in children and adolescents: meta-review of efficacy, tolerability and suicidality in acute treatment
di: Boaden, K, et al.
Pubblicazione: (2020)

Impact of reporting bias in network meta-analysis of antidepressant placebo-controlled trials.
di: Ludovic Trinquart, et al.
Pubblicazione: (2012-01-01)

A dose-effect network meta-analysis model with application in antidepressants using restricted cubic splines
di: Hamza, T, et al.
Pubblicazione: (2022)

Dismantling, optimising, and personalising internet cognitive behavioural therapy for depression: a systematic review and component network meta-analysis using individual participant data
di: Furukawa, TA, et al.
Pubblicazione: (2021)

Comparative efficacy of placebos in short-term antidepressant trials for major depression: a secondary meta-analysis of placebo-controlled trials
di: Lisa Holper, et al.
Pubblicazione: (2020-09-01)

Brexpiprazole versus placebo or other antidepressive agents for treating depression
di: Ralovska, S, et al.
Pubblicazione: (2021)

Personalise antidepressant treatment for unipolar depression combining individual choices, risks and big data (PETRUSHKA): rationale and protocol
di: Toshi A Furukawa, et al.
Pubblicazione: (2020-05-01)

Measuring brain glucose metabolism in order to predict response to antidepressant or placebo: A randomized clinical trial
di: Kathryn R. Hill, et al.
Pubblicazione: (2021-01-01)

Comparative efficacy and tolerability of new-generation antidepressants for major depressive disorder in children and adolescents: protocol of an individual patient data meta-analysis.
di: Zhou, X, et al.
Pubblicazione: (2018)

Visualizing the evolution of evidence: Cumulative network meta-analyses of new generation antidepressants in the last 40 years
di: Luo, Y, et al.
Pubblicazione: (2020)

Selective publication of antidepressant trials and its influence on apparent efficacy: Updated comparisons and meta-analyses of newer versus older trials
di: Erick H. Turner, et al.
Pubblicazione: (2022-01-01)

Selective publication of antidepressant trials and its influence on apparent efficacy: Updated comparisons and meta-analyses of newer versus older trials.
di: Erick H Turner, et al.
Pubblicazione: (2022-01-01)

Initial severity of major depression and efficacy of new generation antidepressants: individual participant data meta‐analysis
di: Furukawa, T, et al.
Pubblicazione: (2018)

Antidepressants in Children and Adolescents: Meta-Review of Efficacy, Tolerability and Suicidality in Acute Treatment
di: Katharine Boaden, et al.
Pubblicazione: (2020-09-01)

Neural Predictors of the Antidepressant Placebo Response
di: Danielle Rette, et al.
Pubblicazione: (2019-10-01)

Quantifying the heterogeneity of cognitive functioning in Alzheimer’s disease to extend the placebo-treatment dichotomy: Latent class analysis of individual-participant data from five pivotal randomized clinical trials of donepezil
di: Levine, SG, et al.
Pubblicazione: (2021)

Disclosing the potential impact of placebo controls in antidepressant trials
di: Stephanie C. Chen, et al.
Pubblicazione: (2015-06-01)

Ranking antidepressants Reply
di: Cipriani, A, et al.
Pubblicazione: (2009)

Personalized prediction of Alzheimer's disease and its treatment effects by donepezil: an individual participant data meta-analysis of eight randomized controlled trials
di: Yoshida, K, et al.
Pubblicazione: (2022)

Initial symptom severity of bipolar I disorder and the efficacy of olanzapine: a meta-analysis of individual participant data from five placebo-controlled studies
di: Samara, MT, et al.
Pubblicazione: (2017)

Safety reporting and adverse-event profile of mirtazapine described in randomized controlled trials in comparison with other classes of antidepressants in the acute-phase treatment of adults with depression: systematic review and meta-analysis.
di: Watanabe, N, et al.
Pubblicazione: (2010)

"Wish bias" in antidepressant drug trials?
di: Barbui, C, et al.
Pubblicazione: (2004)

Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis
di: Cipriani, A, et al.
Pubblicazione: (2016)

Polygenic heterogeneity in antidepressant treatment and placebo response
di: Anne Krogh Nøhr, et al.
Pubblicazione: (2022-10-01)